Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(4.57)
# 321
Out of 5,149 analysts
28
Total ratings
65%
Success rate
26.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMAB Genmab | Initiates: Overweight | $40 | $27.91 | +43.32% | 1 | Mar 2, 2026 | |
| RLAY Relay Therapeutics | Maintains: Overweight | $13 → $15 | $9.72 | +54.32% | 3 | Feb 27, 2026 | |
| RVMD Revolution Medicines | Maintains: Overweight | $100 → $144 | $101.75 | +41.52% | 2 | Feb 26, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Overweight | $50 → $53 | $45.20 | +17.26% | 4 | Feb 25, 2026 | |
| RCUS Arcus Biosciences | Downgrades: Equal-Weight | $30 → $23 | $22.52 | +2.13% | 5 | Feb 12, 2026 | |
| EXEL Exelixis | Maintains: Equal-Weight | $30 → $35 | $41.24 | -15.13% | 1 | Feb 11, 2026 | |
| ZYME Zymeworks | Upgrades: Overweight | $25 → $33 | $25.35 | +30.18% | 4 | Dec 12, 2025 | |
| BCAX Bicara Therapeutics | Maintains: Equal-Weight | $8 → $11 | $17.60 | -37.50% | 3 | Nov 11, 2025 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $60 | $33.01 | +81.76% | 1 | Oct 31, 2025 | |
| XNCR Xencor | Maintains: Overweight | $33 → $27 | $12.40 | +117.74% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $44 | $34.75 | +26.62% | 1 | Jun 26, 2025 |
Genmab
Mar 2, 2026
Initiates: Overweight
Price Target: $40
Current: $27.91
Upside: +43.32%
Relay Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $13 → $15
Current: $9.72
Upside: +54.32%
Revolution Medicines
Feb 26, 2026
Maintains: Overweight
Price Target: $100 → $144
Current: $101.75
Upside: +41.52%
Kiniksa Pharmaceuticals International,
Feb 25, 2026
Maintains: Overweight
Price Target: $50 → $53
Current: $45.20
Upside: +17.26%
Arcus Biosciences
Feb 12, 2026
Downgrades: Equal-Weight
Price Target: $30 → $23
Current: $22.52
Upside: +2.13%
Exelixis
Feb 11, 2026
Maintains: Equal-Weight
Price Target: $30 → $35
Current: $41.24
Upside: -15.13%
Zymeworks
Dec 12, 2025
Upgrades: Overweight
Price Target: $25 → $33
Current: $25.35
Upside: +30.18%
Bicara Therapeutics
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $17.60
Upside: -37.50%
Immunocore Holdings
Oct 31, 2025
Initiates: Overweight
Price Target: $60
Current: $33.01
Upside: +81.76%
Xencor
Aug 7, 2025
Maintains: Overweight
Price Target: $33 → $27
Current: $12.40
Upside: +117.74%
Jun 26, 2025
Initiates: Overweight
Price Target: $44
Current: $34.75
Upside: +26.62%